An open-label study of the capacity of MabThera plus first-line treatment with infusional CDE [cyclophosphamide + doxorubicin + etoposide] to induce a clinical response in patients with HIV-related non-Hodgkin's lymphoma.

Trial Profile

An open-label study of the capacity of MabThera plus first-line treatment with infusional CDE [cyclophosphamide + doxorubicin + etoposide] to induce a clinical response in patients with HIV-related non-Hodgkin's lymphoma.

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Feb 2010

At a glance

  • Drugs Cyclophosphamide; Doxorubicin; Etoposide; Rituximab
  • Indications Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 09 Jun 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top